Paper Details

  1. Home
  2. Paper Details

Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial.

Author: AgotKawango, AhmedKhatija, CorneliAmy, MalamatshoFulufhelo, McKennaKevin, OdhiamboJacob, PerryBrian, SkhosanaJoseph, TaylorJamilah, Van DammeLut

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

A follow-up study of 88 former participants in a clinical trial of daily, oral emtricitabine/tenofovir disoproxil fumarate for HIV prevention found that concerns about the study pill and discouragement from others seemed to have significantly influenced nonadherence. Participants reported concerns about the investigational nature of the drug, side effects, and HIV-related stigma.
Paper Details　
Original Abstract of the Article :
BACKGROUND: FEM-PrEP-a clinical trial of daily, oral emtricitabine/tenofovir disoproxil fumarate for HIV prevention among women in sub-Saharan Africa-did not show a reduction in HIV acquisition because of low adherence to the study pill. We conducted a follow-up study to identify reasons for nonadhe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/QAI.0000000000000880

データ提供：米国国立医学図書館（NLM）

FEM-PrEP Trial: Navigating the Sands of Nonadherence in HIV Prevention

The FEM-PrEP trial, a research effort aimed at preventing HIV infection in women in sub-Saharan Africa, encountered challenges with participant adherence, like a caravan struggling to stay on course in a vast desert. This study delves into the reasons behind this nonadherence, seeking to understand the obstacles that participants faced in adhering to the prescribed medication.

Barriers to Adherence: Shifting Sands of Fear and Uncertainty

The study revealed that concerns about the experimental nature of the medication, potential side effects, and societal stigma related to HIV played a significant role in nonadherence. These concerns, like a sandstorm obscuring the path forward, can make it difficult to embrace new prevention strategies. The study also highlights the impact of discouragement from community members and partners, further complicating the process of adherence.

The Desert of HIV Prevention: Seeking a Clear Path

The desert of HIV prevention requires a multi-faceted approach, addressing not only medical advancements but also social and cultural barriers. This study underscores the importance of addressing these barriers, providing clear and accurate information, fostering open communication, and creating supportive environments where individuals feel comfortable seeking prevention options. The journey toward effective HIV prevention requires careful navigation, addressing both the medical and social landscapes.

Dr.Camel's Conclusion

The study sheds light on the complex reality of HIV prevention, reminding us that the journey toward effective solutions requires a deep understanding of the challenges faced by individuals and communities. By addressing these challenges, we can pave the way for a brighter future, where everyone has access to the tools and resources they need to stay safe and healthy.

Date :
  1. Date Completed 2016-07-06
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

26536315

DOI: Digital Object Identifier

10.1097/QAI.0000000000000880

Related Literature

Article Analysis
・Side Effects of emtricitabine and tenofovir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.